Global PARP (Poly ADP-ribose Polymerase) Inhibitors Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global PARP (Poly ADP-ribose Polymerase) Inhibitors Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
PARP inhibitors are a group of pharmacological inhibitors of the enzyme polymerase ADP ribosome (PARP).They are developed for multiple indications.PARP inhibitors can enhance the efficacy of radiotherapy, alkalization agents and platinum-based chemotherapy by inhibiting DNA damage repair and promoting apoptosis of tumor cells. Parp (Poly Adp-Ribose Polymerase) inhibitors is very effective in treating solid tumors and other diseases.Such as advanced ovarian cancer, fallopian tube cancer and primary peritoneal cancer.
Due to the COVID-19 pandemic, the global PARP (Poly ADP-ribose Polymerase) Inhibitors market size was US$ 2861 million in 2022 and is forecast to a readjusted size of US$ 21490 million by 2034 with a CAGR of 32.8% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Olaparib accounting for % of the PARP (Poly ADP-ribose Polymerase) Inhibitors global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Ovarian Cancer segment is altered to an % CAGR throughout this forecast period.
The global key companies of PARP (Poly ADP-ribose Polymerase) Inhibitors include AbbVie, Pfizer, AstraZeneca, GlaxoSmithKline, Clovis Oncology and Everest Pharmaceuticals, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States PARP (Poly ADP-ribose Polymerase) Inhibitors market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe PARP (Poly ADP-ribose Polymerase) Inhibitors landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global PARP (Poly ADP-ribose Polymerase) Inhibitors market. The analysts authoring the report have closely studied key strategies adopted by top players of the global PARP (Poly ADP-ribose Polymerase) Inhibitors market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global PARP (Poly ADP-ribose Polymerase) Inhibitors market. Readers of the report can become informed about current and future trends of the global PARP (Poly ADP-ribose Polymerase) Inhibitors market and how they will impact market growth during the forecast period.
AbbVie
Pfizer
AstraZeneca
GlaxoSmithKline
Clovis Oncology
Everest Pharmaceuticals
Segment by Type
Olaparib
Talazoparib
Ovarian Cancer
Breast Cancer
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of PARP (Poly ADP-ribose Polymerase) Inhibitors in global and regional level.
Chapter 3Detailed analysis of PARP (Poly ADP-ribose Polymerase) Inhibitors companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PARP (Poly ADP-ribose Polymerase) Inhibitors revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion
Due to the COVID-19 pandemic, the global PARP (Poly ADP-ribose Polymerase) Inhibitors market size was US$ 2861 million in 2022 and is forecast to a readjusted size of US$ 21490 million by 2034 with a CAGR of 32.8% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Olaparib accounting for % of the PARP (Poly ADP-ribose Polymerase) Inhibitors global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Ovarian Cancer segment is altered to an % CAGR throughout this forecast period.
The global key companies of PARP (Poly ADP-ribose Polymerase) Inhibitors include AbbVie, Pfizer, AstraZeneca, GlaxoSmithKline, Clovis Oncology and Everest Pharmaceuticals, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States PARP (Poly ADP-ribose Polymerase) Inhibitors market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe PARP (Poly ADP-ribose Polymerase) Inhibitors landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global PARP (Poly ADP-ribose Polymerase) Inhibitors market. The analysts authoring the report have closely studied key strategies adopted by top players of the global PARP (Poly ADP-ribose Polymerase) Inhibitors market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global PARP (Poly ADP-ribose Polymerase) Inhibitors market. Readers of the report can become informed about current and future trends of the global PARP (Poly ADP-ribose Polymerase) Inhibitors market and how they will impact market growth during the forecast period.
By Company
AbbVie
Pfizer
AstraZeneca
GlaxoSmithKline
Clovis Oncology
Everest Pharmaceuticals
Segment by Type
Olaparib
Talazoparib
Segment by Application
Ovarian Cancer
Breast Cancer
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of PARP (Poly ADP-ribose Polymerase) Inhibitors in global and regional level.
Chapter 3Detailed analysis of PARP (Poly ADP-ribose Polymerase) Inhibitors companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PARP (Poly ADP-ribose Polymerase) Inhibitors revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices